Geoff Martha, CEO of Medtronic, Declares a Surge in Durable Mid-Single Digit Revenue Growth, Backed by Strong Fundamentals and Game-Changing Innovations

Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...

November 22, 2023 | Wednesday | Company results
Bogota's Biopharma Breakthrough: A Strategic Dialogue with Isabella Muñoz, Executive Director of Invest In Bogota

In an exclusive interview with BioPharma BoardRoom, Isabella Muñoz, Executive Director of Invest In Bogota, shares insights into how Bogota has posi...

November 17, 2023 | Friday | Interview
Repligen CEO Tony Hunt Highlights ESG Success in 2022 Progress Report

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its ...

November 15, 2023 | Wednesday | News
Novo Nordisk Executive Vice President, Henrik Wulff, Affirms Commitment with Significant Investment in New API Facility for Global Capacity Expansion

Novo Nordisk  announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg...

November 13, 2023 | Monday | News
Emergent CEO, Haywood Miller, Highlights Financial Growth and Opioid Crisis Response Efforts as Company Pursues Resilient Future.

Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financia...

November 09, 2023 | Thursday | Company results
Gilead's CEO, Daniel O'Day, Steers the Ship to Two Years of Unwavering Growth in Virology and Oncology

Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...

November 08, 2023 | Wednesday | Company results
Pfizer's Dr. Albert Bourla Applauds Q3 2023 Triumphs and Bold Expansion Plans, Paving the Way for a Transformative Future in Oncology and Beyond

Third-Quarter 2023 Revenues of $13.2 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 41% Operational Decrease in Third-Quarter 20...

November 02, 2023 | Thursday | Company results
Revvity's CEO Prahlad Singh Navigates Stormy Q3 Waters, Pledges Stronger Future Amid Market Uncertainty

Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing oper...

October 31, 2023 | Tuesday | Company results
QIAGEN CEO Thierry Bernard Hails Remarkable Quarter, Sees Bright Future on the Horizon

Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Ne...

October 31, 2023 | Tuesday | Company results
Bio-Rad CEO, Norman Schwartz, Discusses Q3 Results and Adjusts 2023 Outlook Amid Biopharma Challenges

  Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 20...

October 30, 2023 | Monday | Company results
Fuelling Growth through Quality: A Candid Conversation with Lars Petersen, President and CEO of FUJIFILM Diosynth Biotechnologies, Unveiling the Key Role of Maja Pedersen

In the bustling halls of CPHI Barcelona, BioPharma BoardRoom had the privilege to sit down with Lars Petersen, the President and CEO of FUJIFILM Diosynth B...

October 27, 2023 | Friday | Interaction
Data and AI in Life Sciences: Shaping the Future - An Exclusive Interview with Mr. Shakti Nagappan, CEO of Telangana Life Sciences

In a rapidly evolving world where data and artificial intelligence have become paramount, BioAsia 2024 presents a theme that transcends traditional boundar...

October 27, 2023 | Friday | Interaction
Marc Casper's Leadership Propels Thermo Fisher to Strong Q3 Performance Amid Market Challenges

Third Quarter 2023 Highlights Third quarter revenue was $10.57 billion, 1% lower versus the same quarter last year. Core organic revenue growth was 1%. ...

October 26, 2023 | Thursday | Company results
Merck CEO Belén Garijo Expresses Confidence in Resilient Growth Model for 2024

Transitional year 2023 managed well so far thanks to resilient business model Medium-term growth targets confirmed Merck expects continued growth also ...

October 25, 2023 | Wednesday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in